This post was originally published on this site.
By Peter Egwuatu
Shareholders of Neimeth International Pharmaceuticals Plc have approved plans by the company’s Board of Directors to raise additional capital to accelerate its expansion programme and complete its ongoing world-class pharmaceutical manufacturing facility in Amawbia, Anambra State.
At the company’s 67th Annual General Meeting (AGM), held virtually, shareholders unanimously approved all the board’s resolutions and called for appropriate timing of the capital raising to ensure full subscription.
Shareholders’ group leaders, including Boniface Okezie, Moses Igbrude, Mrs Bisi Bakare, Alex Adio and Adebayo Adeleke, urged the Board and Management to ensure that the new plant, upon completion, serves as a hub for manufacturing local drugs in the country.
Chairman of the company, Christopher Oshiafi, commended shareholders for their loyalty and support, noting that they had earlier approved a N20 billion capital raise programme, under which the company recently concluded a successful N2.4 billion Rights Issue.
He explained that part of
